CA3121531A1 - Methods of treating a patient having parkinson's disease - Google Patents
Methods of treating a patient having parkinson's disease Download PDFInfo
- Publication number
- CA3121531A1 CA3121531A1 CA3121531A CA3121531A CA3121531A1 CA 3121531 A1 CA3121531 A1 CA 3121531A1 CA 3121531 A CA3121531 A CA 3121531A CA 3121531 A CA3121531 A CA 3121531A CA 3121531 A1 CA3121531 A1 CA 3121531A1
- Authority
- CA
- Canada
- Prior art keywords
- apomorphine
- patient
- dose
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962797660P | 2019-01-28 | 2019-01-28 | |
| US62/797,660 | 2019-01-28 | ||
| US201962861077P | 2019-06-13 | 2019-06-13 | |
| US201962861067P | 2019-06-13 | 2019-06-13 | |
| US62/861,077 | 2019-06-13 | ||
| US62/861,067 | 2019-06-13 | ||
| PCT/US2020/015434 WO2020160005A1 (en) | 2019-01-28 | 2020-01-28 | Methods of treating a patient having parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3121531A1 true CA3121531A1 (en) | 2020-08-06 |
Family
ID=71841403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3121531A Pending CA3121531A1 (en) | 2019-01-28 | 2020-01-28 | Methods of treating a patient having parkinson's disease |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210315882A1 (https=) |
| EP (1) | EP3917502A4 (https=) |
| JP (1) | JP2022518527A (https=) |
| CA (1) | CA3121531A1 (https=) |
| MX (1) | MX2021008986A (https=) |
| WO (1) | WO2020160005A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4578461A3 (en) * | 2015-04-21 | 2025-09-03 | Sumitomo Pharma America, Inc. | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa |
| WO2023172649A1 (en) * | 2022-03-11 | 2023-09-14 | Alexza Pharmaceuticals, Inc. | Apomorphine hydrochloride trimethanolate, its polymorphs and its uses |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2967349B1 (fr) * | 2010-11-15 | 2013-06-14 | Oreal | Composition solide cosmetique de maquillage et/ou de soin |
| EP4578461A3 (en) * | 2015-04-21 | 2025-09-03 | Sumitomo Pharma America, Inc. | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa |
-
2020
- 2020-01-28 EP EP20749249.7A patent/EP3917502A4/en active Pending
- 2020-01-28 MX MX2021008986A patent/MX2021008986A/es unknown
- 2020-01-28 CA CA3121531A patent/CA3121531A1/en active Pending
- 2020-01-28 WO PCT/US2020/015434 patent/WO2020160005A1/en not_active Ceased
- 2020-01-28 JP JP2021543164A patent/JP2022518527A/ja active Pending
-
2021
- 2021-06-10 US US17/344,314 patent/US20210315882A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3917502A4 (en) | 2022-10-12 |
| US20210315882A1 (en) | 2021-10-14 |
| JP2022518527A (ja) | 2022-03-15 |
| WO2020160005A1 (en) | 2020-08-06 |
| EP3917502A1 (en) | 2021-12-08 |
| MX2021008986A (es) | 2021-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8642648B2 (en) | Orally dispersible tablet | |
| CN1323664C (zh) | 雷诺嗪缓释制剂 | |
| US20110166220A1 (en) | Dronedarone for the prevention of permanent atrial fibrillation | |
| US10959943B2 (en) | Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa | |
| JP2008069159A5 (https=) | ||
| HU224215B1 (hu) | Késleltetett felszabadulású ranolazinkészítmények | |
| US12128027B2 (en) | N—N-dimethyltryptamine (DMT) and DMT analog compositions, methods of making, and methods of use thereof | |
| JP2015221826A (ja) | イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物 | |
| US20210315882A1 (en) | Methods of treating a patient having parkinson's disease | |
| EP2768487B1 (en) | Sustained-release preparation | |
| KR20230084186A (ko) | 덱스메데토미딘 하이드로클로라이드를 사용한 양극성 장애 및 정신병의 치료 | |
| EP4076381B1 (en) | Transmucosal therapeutic system containing agomelatine | |
| US20250281448A1 (en) | Cardioversion Methods Using Budiodarone | |
| JP6061924B2 (ja) | 口腔内分散性製剤 | |
| US8602215B2 (en) | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation | |
| TW201626990A (zh) | 含有褪黑激素和舍曲林的口服複合錠劑 | |
| HK40110942A (en) | Transmucosal therapeutic system containing agomelatine | |
| HK40082930B (en) | Transmucosal therapeutic system containing agomelatine | |
| HK40082930A (en) | Transmucosal therapeutic system containing agomelatine | |
| KR20120103521A (ko) | 에페리손 함유 필름코팅정제, 및 이의 제조방법 | |
| HK1058003B (en) | Sustained release ranolazine formulations | |
| TW201208676A (en) | Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular hospitalization or of mortality in patients with lone atrial fibrillation |